Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine

Drug Metabolism and Disposition

Volumn 35, Issue 7, 2007, Pages 1165-1173

  Pan, Guoyu ^a   Giri, Nagdeep ^a   Elmquist, William F ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; BREAST CANCER RESISTANCE PROTEIN; ELACRIDAR; KO 143; NUCLEOSIDE; PROBENECID; UNCLASSIFIED DRUG; ZIDOVUDINE;

APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; BRAIN CAPILLARY; CELL TRANSPORT; COMPARATIVE STUDY; CORRELATION COEFFICIENT; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG INHIBITION; DRUG TRANSPORT; EFFUSION; ENDOTHELIUM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INTESTINE CELL; KIDNEY CELL; LYMPHOCYTE; MODEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; WILD TYPE;

ACRIDINES; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL LINE; CELL MEMBRANE PERMEABILITY; DIDEOXYNUCLEOSIDES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; REVERSE TRANSCRIPTASE INHIBITORS; TETRAHYDROISOQUINOLINES; TIME FACTORS; TRANSFECTION; ZIDOVUDINE;

MURINAE;

EID: 34250695989     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.014274     Document Type: Article

References (39)

1. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JH, Koomen GJ, and Schinkel AH (2002) Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1:417-425.
2. Bagasra O, Lavi E, Bobroski L, Khalili K, Pestaner JP, Tawadros R, and Pomerantz RJ (1996) Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS 10:573-585.
3. Baker R (1997) 3-Drug therapy reduces deaths and new AIDS-related illnesses by 50%. BETA March:3-4.
4. Cooray HC, Blackmore CG, Maskell L, and Barrand MA (2002) Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 13:2059-2063.
5. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, and Melamed MR (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277-1287.
6. Cretton EM, Schinazi RF, McClure HM, Anderson DC, and Sommadossi JP (1991) Pharmacokinetics of 3′-azido-3′-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys. Antimicrob Agents Chemother 35:801-807.
7. Daluge SM, Good SS, Faletto MB, Miller WH, St. Clair MH, Boone LR, Tisdale M, Parry NR, Reardon JE, Dornsife RE, et al. (1997) 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 41:1082-1093.
8. Donnerer J, Kronawetter M, Kapper A, Haas I, and Kessler HH (2003) Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. Pharmacology 69:197-204.
9. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95:15665-15670.
10. Ezzell C (1987) AZT given the green light for clinical treatment of AIDS. Nature 326:430.
11. Gibbs JE and Thomas SA (2002) The distribution of the anti-HIV drug, 2′3′-dideoxycytidine (ddC), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors. J Neurochem 80:392-404.
12. Gupta A, Zhang Y, Unadkat JD, and Mao Q (2004) HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 310:334-341.
13. Hori S, Ohtsuki S, Tachikawa M, Kimura N, Kondo T, Watanabe M, Nakashima E, and Terasaki T (2004) Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s). J Neurochem 90:526-536.
14. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, and Schinkel AH (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651-1656.
15. Jorajuria S, Dereuddre-Bosquet N, Becher F, Martin S, Porcheray F, Garrigues A, Mabondzo A, Benech H, Grassi J, Orlowski S, et al. (2004) ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther 9:519-528.
16. Kessler HA (2005) Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review. Med Gen Med 7:70.
17. Kure K, Llena JF, Lyman WD, Soeiro R, Weidenheim KM, Hirano A, and Dickson DW (1991) Human immunodeficiency virus-1 infection of the nervous system: an autopsy study of 268 adult, pediatric, and fetal brains. Hum Pathol 22:700-710.
18. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, and Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
19. Mallants R, Van Oosterwyck K, Van Vaeck L, Mols R, De Clercq E, and Augustijns P (2005) Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica 35:1055-1066.
20. McDowell JA, Chittick GE, Ravitch JR, Polk RE, Kerkering TM, and Stein DS (1999) Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother 43:2855-2861.
21. Minderman H, Suvannasankha A, O'Loughlin KL, Scheffer GL, Scheper RJ, Robey RW, and Baer MR (2002) Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry 48:59-65.
22. Mohri M, Nitta H, and Yamashita J (2000) Expression of multidrug resistance-associated protein (MRP) in human gliomas. J Neurooncol 49:105-115.
23. Mohrmann K, van Eijndhoven MA, Schinkel AH, and Schellens JH (2005) Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). Cancer Chemother Pharmacol 56:344-350.
24. Park S and Sinko PJ (2005) P-glycoprotein and multidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J Pharmacol Exp Ther 312:1249-1256.
25. Pialoux G, Fournier S, Moulignier A, Poveda JD, Clavel F, and Dupont B (1997) Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir. AIDS 11:1302-1303.
26. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, and Meier PJ (2002) Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol 16:2283-2296.
27. Polli JW, Baughman TM, Humphreys JE, Jordan KH, Mote AL, Salisbury JA, Tippin TK, and Serabjit-Singh CJ (2003) P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. J Pharm Sci 92:2082-2089.
28. Pomerantz RJ and Horn DL (2003) Twenty years of therapy for HIV-1 infection. Nat Med 9:867-873.
29. Sawchuk RJ and Yang Z (1999) Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. Adv Drug Deliv Rev 39:5-31.
30. Scheffer GL, Maliepaard M, Pijnenborg AC, van Gastelen MA, de Jong MC, Schroeijers AB, van der Kolk DM, Allen JD, Ross DD, van der Valk P, et al. (2000) Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res 60:2589-2593.
31. Sun H, Dai H, Shaik N, and Elmquist WF (2003) Drug efflux transporters in the CNS. Adv Drug Deliv Rev 55:83-105.
32. Takasawa K, Terasaki T, Suzuki H, and Sugiyama Y (1997) In vivo evidence for carrier-mediated efflux transport of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. J Pharmacol Exp Ther 281:369-375.
33. Thomas SA, Bye A, and Segal MB (2001) Transport characteristics of the anti-human immunodeficiency virus nucleoside analog, abacavir, into brain and cerebrospinal fluid. J Pharmacol Exp Ther 298:947-953.
34. Wang E, Casciano CN, Clement RP, and Johnson WW (2000) Cooperativity in the inhibition of p-glycoprotein-mediated daunorubicin transport: evidence for half-of-the-sites reactivity. Arch Biochem Biophys 383:91-98.
35. Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, and Baba M (2003) Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol 63:65-72.
36. Wang X, Nitanda T, Shi M, Okamoto M, Furukawa T, Sugimoto Y, Akiyama S, and Baba M (2004) Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. Biochem Pharmacol 68:1363-1370.
37. Wang Y, Wei Y, and Sawchuk RJ (1997) Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. J Pharm Sci 86:1484-1490.
38. Werber Y (2003) HIV drug market. Nat Rev Drug Discov 2:513-514.
39. Wong SL, Van Belle K, and Sawchuk RJ (1993) Distributional transport kinetics of zidovudine between plasma and brain extracellular fluid/cerebrospinal fluid in the rabbit: investigation of the inhibitory effect of probenecid utilizing microdialysis. J Pharmacol Exp Ther 264:899-909.